Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMGN REGN VRTX BIIB GILD INCY ALKS NBIX AMRN EXEL

| Held by: XBI VTI IWM VXF IWN VTWO SCHA FESM VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	4.61%	Shs Outstand	265.23M	Perf Week	1.46%
Market Cap	371.57M	Forward P/E	20.59	EPS next Y	0.07	Insider Trans	-5.03%	Shs Float	253.13M	Perf Month	1.46%
Enterprise Value	416.72M	PEG	0.37	EPS next Q	-0.03	Inst Own	48.59%	Short Float	14.59%	Perf Quarter	-22.64%
Income	-15.90M	P/S	1.65	EPS this Y	103.03%	Inst Trans	3.94%	Short Ratio	10.74	Perf Half Y	-57.57%
Sales	225.07M	P/B	8.93	EPS next Y	580.00%	ROA	-5.57%	Short Interest	36.93M	Perf YTD	-13.03%
Book/sh	0.16	P/C	2.21	EPS next 5Y	55.04%	ROE	-	52W High	4.08 -65.67%	Perf Year	-33.64%
Cash/sh	0.63	P/FCF	11.55	EPS past 3/5Y	42.15% 32.58%	ROIC	-7.21%	52W Low	1.30 7.71%	Perf 3Y	74.48%
Dividend Est.	-	EV/EBITDA	12.93	Sales past 3/5Y	-8.87% -13.72%	Gross Margin	76.55%	Volatility	7.11% 6.19%	Perf 5Y	-69.63%
Dividend TTM	-	EV/Sales	1.85	EPS Y/Y TTM	65.88%	Oper. Margin	7.88%	ATR (14)	0.10	Perf 10Y	-81.79%
Dividend Ex-Date	-	Quick Ratio	1.80	Sales Y/Y TTM	32.49%	Profit Margin	-7.07%	RSI (14)	44.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.94	EPS Q/Q	102.10%	SMA20	-1.22%	Beta	0.37	Target Price	4.60
Payout	-	Debt/Eq	5.13	Sales Q/Q	57.01%	SMA50	-7.35%	Rel Volume	1.68	Prev Close	1.55
Employees	181	LT Debt/Eq	4.30	Earnings	Nov 10 BMO	SMA200	-46.34%	Avg Volume	3.44M	Price	1.40
IPO	Mar 20, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% 0.92%	Trades		Volume	5,160,738	Change	-9.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-25	Resumed	H.C. Wainwright	Buy	$8
Apr-28-25	Initiated	Leerink Partners	Outperform	$7
Apr-01-25	Initiated	Jefferies	Buy	$6
Nov-29-23	Resumed	BTIG Research	Buy	$4
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$3.75
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral	$8 → $2
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Mizuho	Buy → Neutral	$6 → $2
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $2
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight	$8
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy	$18 → $15
Aug-06-19	Reiterated	H.C. Wainwright	Buy	$19 → $17
Jul-11-19	Reiterated	H.C. Wainwright	Buy	$23 → $21
May-02-19	Initiated	JP Morgan	Overweight	$12
Mar-20-19	Initiated	Citigroup	Neutral	$9
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy	$20 → $18
Jun-06-18	Reiterated	H.C. Wainwright	Buy	$24 → $22

Show Previous Ratings

Today 10:34AM	Akebia Therapeutics Spotlights VAFSEO Dialysis Push, TIW Dosing Plan and Rare Kidney Pipeline at Summit (MarketBeat) -9.66%
Feb-04-26 08:00AM	Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 08:00AM	Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook (GlobeNewswire) -7.89%
Jan-07-26 08:22AM	Akebia announces first patient dosed in Phase 2 trial of praliciguat (TipRanks)
08:00AM	Loading…
Jan-06-26 08:00AM	Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) (GlobeNewswire)
Jan-05-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-25 12:46PM	Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat (Insider Monkey)
Dec-02-25 11:28AM	This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? (Barchart)
Dec-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Q32 Bio Sells Complement Inhibitor ADX-097 (PR Newswire)
07:00AM	Akebia Announces Establishment of Rare Kidney Disease Pipeline (GlobeNewswire)
Nov-24-25 08:00AM	Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 11:01AM	Implied Volatility Surging for Akebia Therapeutics Stock Options (Zacks)
Nov-11-25 10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks) +8.38%
09:35AM	Loading…
09:35AM	Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-10-25 02:01PM	Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) -18.14%
07:00AM	Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-25 12:51PM	Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y (Zacks)
Nov-06-25 06:55PM	Globus Medical (GMED) Tops Q3 Earnings and Revenue Estimates (Zacks) -5.19%
06:30PM	Vafseo (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs (GlobeNewswire)
Nov-05-25 05:50PM	Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-25 08:00AM	Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Oct-28-25 04:30PM	Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients (GlobeNewswire) -32.04%
Oct-20-25 08:08AM	Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025 (GlobeNewswire) +7.85%
Oct-15-25 06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks) +5.73%
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
Oct-08-25 09:40AM	Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? (Zacks)
04:05PM	Loading…
Oct-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-25 03:48AM	Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? (Zacks)
Sep-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-25 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 08:00AM	Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo (vadadustat) Across All IRC Dialysis Clinics (GlobeNewswire)
Aug-20-25 12:22AM	Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth (Insider Monkey)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -20.48%
08:25AM	Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 (Zacks)
07:00AM	Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference (GlobeNewswire)
Aug-04-25 08:00AM	Akebia Initiates Vafseo (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization (GlobeNewswire)
Aug-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:40AM	Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year? (Zacks)
Jul-31-25 08:00AM	Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Jul-25-25 12:09PM	H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy (Insider Monkey) -7.29%
Jul-22-25 11:03AM	Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share (Insider Monkey)
Jul-16-25 12:00PM	Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
09:40AM	Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-08-25 08:00AM	Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference (GlobeNewswire)
Jul-07-25 09:10AM	Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT (Insider Monkey)
Jul-02-25 10:08PM	Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase (Insider Monkey)
Jul-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:42AM	Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials (Insider Monkey)
Jun-17-25 09:53AM	Averoa secures EC authorisation for oral CKD treatment (Pharmaceutical Technology)
Jun-04-25 08:00AM	Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology (GlobeNewswire) +6.43%
Jun-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.26% +5.23%
May-28-25 08:00AM	Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-27-25 08:00AM	Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 (GlobeNewswire)
May-13-25 08:00AM	Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-09-25 03:11AM	Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... (GuruFocus.com)
May-08-25 08:15AM	Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates (Zacks) +6.50%
07:18AM	Akebia Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha) +6.03%
05:30PM	Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
12:35PM	Akebia Q1 2025 Earnings Preview (Seeking Alpha)
10:44AM	Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result (GuruFocus.com)
May-01-25 04:15PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:00AM	Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Apr-10-25 08:56AM	Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock (Zacks) -8.82%
Apr-03-25 08:00AM	Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL , an Oral Therapy for Chronic Kidney Disease Licensed to Averoa (GlobeNewswire)
Apr-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-25 08:00AM	Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 (GlobeNewswire)
Mar-21-25 01:01PM	Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering (Zacks)
12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks)
09:19AM	Akebia's Valuation Looks Stretched Despite Auryxia's Loss Of Exclusivity (SeekingAlpha)
07:06AM	Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday? (InsiderMonkey)
Mar-20-25 05:00AM	Biggest stock movers Thursday: YY, FIVE, and more (SeekingAlpha) -28.17%
Mar-19-25 10:17PM	Akebia Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +11.37%
04:36PM	Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game? (InsiderMonkey)
04:01PM	Akebia Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-14-25 03:03AM	Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ... (GuruFocus.com) +33.73%
Mar-13-25 11:32PM	Q4 2024 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -12.44%
08:10AM	Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:09AM	Akebia Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo (vadadustat) Commercial Launch Progress Update (GlobeNewswire)
Mar-06-25 08:00AM	Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Mar-04-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-04-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-25 08:28AM	Akebia announces multiple positive business updates (TipRanks)
Jan-13-25 08:00AM	Akebia Therapeutics Announces Multiple Positive Business Updates (PR Newswire) +6.86%
Jan-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-18-24 08:00AM	Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.88%
Dec-03-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo (vadadustat) for CKD Patients on Dialysis (PR Newswire)
Nov-25-24 08:00AM	Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference (PR Newswire)
Nov-14-24 08:00AM	Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease (PR Newswire)
Nov-12-24 08:00AM	Akebia Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malabre Richard C	SVP, Chief Accounting Officer	Feb 02 '26	Sale	1.39	49,524	68,838	299,390	Feb 04 04:15 PM
Grund Nicholas	Chief Commercial Officer	Feb 02 '26	Sale	1.39	84,829	117,912	561,750	Feb 04 04:13 PM
Burke Steven Keith	SVP, Chief Medical Officer	Feb 02 '26	Sale	1.39	67,658	94,045	948,432	Feb 04 04:13 PM
Rucci Carolyn M.	SVP, Chief Legal Officer	Feb 02 '26	Sale	1.39	69,772	96,983	588,378	Feb 04 04:12 PM
Ostrowski Erik	SVP, CFO, CBO & Treasurer	Feb 02 '26	Sale	1.39	34,951	48,582	672,635	Feb 04 04:11 PM
Butler John P.	CEO and President	Feb 02 '26	Sale	1.39	341,305	474,414	3,206,233	Feb 04 04:10 PM
Ostrowski Erik	Officer	Feb 02 '26	Proposed Sale	1.39	34,951	48,739		Feb 02 05:58 PM
Grund Nicholas	Officer	Feb 02 '26	Proposed Sale	1.39	84,829	118,294		Feb 02 05:57 PM
Burke Steven Keith	Officer	Feb 02 '26	Proposed Sale	1.39	67,658	94,349		Feb 02 05:55 PM
Butler John P.	Officer	Feb 02 '26	Proposed Sale	1.39	341,305	475,950		Feb 02 05:54 PM
Rucci Carolyn M.	Officer	Feb 02 '26	Proposed Sale	1.39	69,772	97,297		Feb 02 05:52 PM
Ostrowski Erik	SVP, CFO, CBO & Treasurer	Jun 30 '25	Sale	3.67	41,314	151,622	503,586	Jul 01 05:01 PM
Ostrowski Erik	Officer	Jun 30 '25	Proposed Sale	3.67	41,314	151,622		Jun 30 05:46 PM
Malabre Richard C	SVP, Chief Accounting Officer	Jun 09 '25	Option Exercise	1.68	15,000	25,200	281,914	Jun 11 05:13 PM
Malabre Richard C	SVP, Chief Accounting Officer	Jun 09 '25	Sale	4.01	15,000	60,150	266,914	Jun 11 05:13 PM
Malabre Richard C	SVP, Chief Accounting Officer	Jun 04 '25	Sale	3.53	13,334	47,069	266,914	Jun 05 04:35 PM
Butler John P.	CEO and President	Mar 03 '25	Sale	1.83	46,409	84,928	2,557,921	Mar 04 05:05 PM
Burke Steven Keith	SVP, Chief Medical Officer	Mar 03 '25	Sale	1.83	7,144	13,074	809,090	Mar 04 05:04 PM
Burke Steven Keith	Officer	Mar 03 '25	Proposed Sale	1.83	7,144	13,086		Mar 03 05:39 PM
Butler John P.	Officer	Mar 03 '25	Proposed Sale	1.83	46,409	85,007		Mar 03 05:37 PM

Open in Screener

VCEL

Vericel Corp

Feb 12 • 03:16PM ET

34.31

-0.32 -0.92 %

Healthcare • Biotechnology • USA • NASD

Peers: MDXG ATRC OFIX PODD RVNC ICUI HAE APYX CUTR ENZ

| Held by: IJR VTI XBI IWM VXF SPSM IJT IWO IBB VTWO

Index	RUT	P/E	142.48	EPS (ttm)	0.24	Insider Own	1.07%	Shs Outstand	50.55M	Perf Week	-3.02%
Market Cap	1.74B	Forward P/E	60.82	EPS next Y	0.56	Insider Trans	-7.46%	Shs Float	50.03M	Perf Month	-7.40%
Enterprise Value	1.70B	PEG	0.92	EPS next Q	0.39	Inst Own	105.74%	Short Float	9.20%	Perf Quarter	-16.42%
Income	13.08M	P/S	6.71	EPS this Y	33.15%	Inst Trans	-3.36%	Short Ratio	8.38	Perf Half Y	-9.54%
Sales	258.72M	P/B	5.39	EPS next Y	111.82%	ROA	3.10%	Short Interest	4.60M	Perf YTD	-4.72%
Book/sh	6.37	P/C	12.82	EPS next 5Y	66.06%	ROE	4.52%	52W High	58.77 -41.62%	Perf Year	-38.75%
Cash/sh	2.68	P/FCF	85.14	EPS past 3/5Y	- -	ROIC	3.21%	52W Low	29.24 17.34%	Perf 3Y	18.88%
Dividend Est.	-	EV/EBITDA	99.74	Sales past 3/5Y	14.95% 15.02%	Gross Margin	73.81%	Volatility	4.74% 4.40%	Perf 5Y	-32.30%
Dividend TTM	-	EV/Sales	6.57	EPS Y/Y TTM	241.86%	Oper. Margin	2.75%	ATR (14)	1.63	Perf 10Y	1754.59%
Dividend Ex-Date	-	Quick Ratio	4.47	Sales Y/Y TTM	14.05%	Profit Margin	5.06%	RSI (14)	38.64	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.87	EPS Q/Q	631.52%	SMA20	-6.31%	Beta	1.23	Target Price	54.50
Payout	0.00%	Debt/Eq	0.31	Sales Q/Q	16.58%	SMA50	-7.33%	Rel Volume	0.29	Prev Close	34.63
Employees	357	LT Debt/Eq	0.27	Earnings	Nov 06 BMO	SMA200	-8.75%	Avg Volume	549.07K	Price	34.31
IPO	Feb 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	1687.30% 4.56%	Trades		Volume	144,338	Change	-0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Downgrade	BTIG Research	Buy → Neutral
Aug-09-24	Initiated	Canaccord Genuity	Buy	$57
Jun-20-24	Initiated	TD Cowen	Buy	$55
Jan-25-24	Upgrade	Truist	Hold → Buy	$39 → $51
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy	$39
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight	$40
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight	$31
Sep-17-20	Initiated	Truist	Buy	$24
Oct-09-19	Initiated	H.C. Wainwright	Buy	$19
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy	$15 → $14
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform	$15
Mar-06-18	Reiterated	Needham	Buy	$5 → $15
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-05-18	Reiterated	BTIG Research	Buy	$8 → $13
Jun-21-17	Initiated	BTIG Research	Buy	$6

Show Previous Ratings

Today 08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-13-26 12:57PM	Why Is Vericel Stock Gaining Tuesday? (Benzinga)
09:00AM	Vericel Announces Preliminary 2025 Financial Results and Business Updates (GlobeNewswire)
Jan-06-26 08:30AM	Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 (GlobeNewswire) +6.09%
Dec-21-25 09:57AM	Truist Slashes PT on Vericel Corporation (VCEL) to $45 From $50 (Insider Monkey)
08:30AM	Loading…
Nov-14-25 08:30AM	Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025 (GlobeNewswire)
Nov-10-25 09:55AM	Wall Street Analysts Believe Vericel (VCEL) Could Rally 39.42%: Here's is How to Trade (Zacks)
Nov-06-25 04:01PM	Vericel Corp (VCEL) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
09:10AM	Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates (Zacks)
07:55AM	Vericel Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-31-25 09:15AM	Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? (Zacks)
Oct-23-25 08:30AM	Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-22-25 08:48AM	Here's Why Vericel Corporation (VCEL) Underperformed in Q3 (Insider Monkey)
Oct-20-25 11:08PM	Truist Lowers PT on Vericel Corporation (VCEL) to $41 From $46 (Insider Monkey)
Sep-12-25 08:53AM	Here's Why Vericel Corp. (VCEL) Traded Down in Q2 (Insider Monkey)
03:46PM	Loading…
Sep-11-25 03:46PM	Is the Options Market Predicting a Spike in Vericel Stock? (Zacks) +7.09%
Aug-28-25 08:30AM	Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025 (GlobeNewswire)
Aug-20-25 12:13AM	Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating (Insider Monkey)
Jul-31-25 09:15AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.07%
08:08AM	Vericel Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-30-25 09:44AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result (GuruFocus.com)
09:00AM	Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-24-25 09:47AM	Vericel Corporation (VCEL): A Bull Case Theory (Insider Monkey)
Jul-17-25 08:30AM	Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025 (GlobeNewswire)
Jun-10-25 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025 (GlobeNewswire)
May-09-25 03:13AM	Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
May-08-25 09:05AM	Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:45AM	Vericel Corporation (VCEL): Among Stocks with Insanely High PE Ratios Insiders Are Selling (Insider Monkey)
07:55AM	Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance (GlobeNewswire)
May-07-25 02:18PM	Vericel Q1 2025 Earnings Preview (Seeking Alpha) +5.25%
10:08AM	Loading…
10:08AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q1 2025 Result (GuruFocus.com)
08:30AM	Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 (GlobeNewswire)
May-06-25 05:35PM	Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-01-25 05:15PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-30-25 08:39AM	Vericel Corp. (VCEL) Faces Challenges as Burn Care Revenue Wanes and MACI Growth Remains Uncertain (Insider Monkey)
Apr-24-25 08:30AM	Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Mar-04-25 08:30AM	Vericel to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-28-25 02:11AM	Vericel Corp (VCEL) Q4 2024 Earnings Call Highlights: Record Revenue and Strong Growth Trajectory (GuruFocus.com)
01:51AM	Q4 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:05AM	Vericel Corporation (VCEL) Tops Q4 Earnings Estimates (Zacks) -6.11%
07:54AM	Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 07:28AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q4 2024 Result (GuruFocus.com)
Feb-13-25 08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Jan-14-25 04:05PM	Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets (GlobeNewswire)
Jan-08-25 08:30AM	Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 (GlobeNewswire)
Dec-19-24 07:36AM	Vericel price target raised to $67 from $61 at Truist (TipRanks)
Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily) +5.15%
Nov-08-24 04:03AM	Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ... (GuruFocus.com) +7.94%
Nov-07-24 09:10AM	Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 07:15AM	Vericel Corp (VCEL) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +7.35%
Oct-24-24 08:30AM	Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-22-24 09:31AM	Vericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First Half (Insider Monkey)
Oct-18-24 03:04PM	State Street Corp's Strategic Reduction in Vericel Corp Holdings (GuruFocus.com)
Oct-09-24 03:44PM	Vericel Corp (VCEL) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
Aug-29-24 09:17AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 (GlobeNewswire)
Aug-26-24 07:45AM	Vericel Announces FDA Approval and Commercial Availability of MACI Arthro (GlobeNewswire)
Aug-16-24 10:33AM	MediWound and Vericel win FDA paediatric label expansion for NexoBrid (Medical Device Network)
Aug-15-24 04:05PM	Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns (GlobeNewswire)
Aug-07-24 08:30AM	Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 (GlobeNewswire)
Aug-05-24 12:00PM	What Makes Vericel (VCEL) a New Strong Buy Stock (Zacks)
Aug-01-24 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.94%
07:55AM	Vericel Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-29-24 03:45PM	AppFolio, Inc. (APPF): One of Ray Dalio's Top 10 Growth Stock Picks Right Now? (Insider Monkey)
Jul-22-24 08:30AM	Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer (GlobeNewswire)
Jul-18-24 08:30AM	Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jul-16-24 07:01PM	Insider Sale: CFO Mara Joseph Anthony Jr Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jul-02-24 09:58AM	Should You Consider Adding Vericel Corporation (VCEL) to Your Portfolio? (Insider Monkey)
Jun-27-24 02:03PM	The 3 Highest-Rated Medical Stocks You Can Buy Today (InvestorPlace)
Jun-25-24 07:22AM	Factors Behind Vericel Corporation (VCEL) Stock's Positive Momentum (Insider Monkey)
Jun-20-24 09:54AM	Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls (The Fly)
Jun-11-24 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 (GlobeNewswire)
May-22-24 08:30AM	Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 (GlobeNewswire)
May-21-24 06:42AM	Multiple Factors Pushed Vericel Corp. (VCEL) in Q1 (Insider Monkey)
May-09-24 03:28PM	Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:08AM	Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-08-24 11:24PM	Q1 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Vericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core Markets (GuruFocus.com)
09:10AM	Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell (MT Newswires)
07:55AM	Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance (GlobeNewswire)
Apr-24-24 08:30AM	Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Mar-29-24 07:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
Mar-28-24 01:48PM	Land Developer And A Specialty Medical Stock Burst Into Buy Zones (Investor's Business Daily)
Mar-15-24 07:00PM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Mar-01-24 09:30AM	Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:37PM	Q4 2023 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Vericel Corporation (VCEL) Q4 Earnings Beat Estimates (Zacks)
08:32AM	Vericel Corp (VCEL) Reports Robust Revenue and EBITDA Growth in Q4 and Full-Year 2023 (GuruFocus.com)
07:55AM	Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance (GlobeNewswire)
Feb-27-24 08:30AM	Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 (GlobeNewswire)
Feb-22-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice (Zacks)
Feb-18-24 03:00AM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Feb-15-24 10:00AM	Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
08:50AM	Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 08:30AM	Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024 (GlobeNewswire)
Jan-30-24 11:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
08:50AM	Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why (Zacks)
Jan-25-24 09:49AM	Tesla, Boeing downgraded: Wall Street's top analyst calls (The Fly)
Jan-24-24 07:01PM	Director ZERBE ROBERT L MD Sells 8,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCLAUGHLIN KEVIN F	Director	Feb 11 '26	Proposed Sale	35.62	7,000	249,340		Feb 11 10:07 AM
Halpin Michael	Chief Operating Officer	Jan 07 '26	Option Exercise	16.66	10,000	166,600	26,080	Jan 09 04:05 PM
Halpin Michael	Chief Operating Officer	Jan 07 '26	Sale	40.48	10,000	404,800	16,080	Jan 09 04:05 PM
Halpin Michael	Officer	Jan 07 '26	Proposed Sale	40.48	10,000	404,833		Jan 07 04:22 PM
Mahoney Karen	Chief Human Resources Officer	Jul 22 '25	Option Exercise	0.00	2,625	0	2,625	Dec 12 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Dec 02 '25	Option Exercise	18.00	1,652	29,736	68,214	Dec 04 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Dec 02 '25	Sale	39.14	1,652	64,659	66,562	Dec 04 04:05 PM
Wotton Paul K	Director	Dec 02 '25	Sale	37.97	2,500	94,925	28,102	Dec 04 04:05 PM
Wotton Paul K	Director	Dec 03 '25	Sale	37.83	2,500	94,575	25,602	Dec 04 04:05 PM
Wotton Paul K	Director	Dec 03 '25	Proposed Sale	37.83	2,500	94,575		Dec 03 11:25 AM
Wotton Paul K	Director	Dec 02 '25	Proposed Sale	37.97	2,500	94,919		Dec 02 04:08 PM
Hopper Jonathan Mark	Officer	Dec 02 '25	Proposed Sale	39.14	1,652	64,659		Dec 02 10:10 AM
Halpin Michael	Chief Operating Officer	Nov 11 '25	Option Exercise	16.66	2,642	44,016	18,574	Nov 13 04:05 PM
Halpin Michael	Chief Operating Officer	Nov 11 '25	Sale	40.41	2,642	106,763	15,932	Nov 13 04:05 PM
MCLAUGHLIN KEVIN F	Director	Nov 10 '25	Option Exercise	2.63	7,000	18,410	22,100	Nov 12 04:06 PM
MCLAUGHLIN KEVIN F	Director	Nov 10 '25	Sale	38.59	7,000	270,130	15,100	Nov 12 04:06 PM
Halpin Michael	Officer	Nov 11 '25	Proposed Sale	40.41	2,642	106,760		Nov 12 07:33 AM
Halpin Michael	Chief Operating Officer	Nov 06 '25	Option Exercise	16.66	7,358	122,584	23,290	Nov 10 04:05 PM
Halpin Michael	Chief Operating Officer	Nov 06 '25	Sale	40.47	7,358	297,778	15,932	Nov 10 04:05 PM
MCLAUGHLIN KEVIN F	Director	Nov 10 '25	Proposed Sale	39.71	7,000	277,970		Nov 10 02:47 PM
Halpin Michael	Officer	Nov 06 '25	Proposed Sale	40.47	7,358	297,775		Nov 06 04:19 PM
SIEGAL JONATHAN	Principal Accounting Officer	Sep 30 '25	Option Exercise	0.00	938	0	2,440	Oct 02 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Sep 02 '25	Option Exercise	18.00	10,000	180,000	76,363	Sep 03 04:06 PM
Hopper Jonathan Mark	Chief Medical Officer	Sep 02 '25	Sale	35.77	10,000	357,700	66,363	Sep 03 04:06 PM
Hopper Jonathan Mark	Officer	Sep 02 '25	Proposed Sale	35.77	10,000	357,700		Sep 02 12:14 PM
MCLAUGHLIN KEVIN F	Director	Aug 06 '25	Option Exercise	2.76	7,000	19,320	22,100	Aug 08 04:05 PM
MCLAUGHLIN KEVIN F	Director	Aug 06 '25	Sale	35.92	7,000	251,440	15,100	Aug 08 04:05 PM
MCLAUGHLIN KEVIN F	Director	Aug 06 '25	Proposed Sale	35.92	7,000	251,457		Aug 06 05:18 PM
Hopper Jonathan Mark	Chief Medical Officer	Jun 02 '25	Option Exercise	18.00	10,000	180,000	76,237	Jun 04 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Jun 02 '25	Sale	40.09	10,000	400,900	66,237	Jun 04 04:05 PM
Hopper Jonathan Mark	Officer	Jun 02 '25	Proposed Sale	41.13	10,000	411,300		Jun 02 10:50 AM
GILMAN STEVEN C	Former Director	May 30 '25	Proposed Sale	42.00	13,125	551,250		May 30 03:58 PM
Colangelo Dominick	President and CEO	May 15 '25	Option Exercise	2.65	14,063	37,267	274,417	May 16 04:06 PM
Colangelo Dominick	President and CEO	May 14 '25	Option Exercise	2.65	14,062	37,264	274,416	May 16 04:06 PM
Colangelo Dominick	President and CEO	May 14 '25	Sale	42.25	14,062	594,120	260,354	May 16 04:06 PM
Colangelo Dominick	President and CEO	May 15 '25	Sale	41.53	14,063	584,036	260,354	May 16 04:06 PM
Colangelo Dominick	Officer	May 15 '25	Proposed Sale	42.26	14,063	594,302		May 15 10:29 AM
Colangelo Dominick	Officer	May 14 '25	Proposed Sale	43.29	14,062	608,744		May 14 09:47 AM
MCLAUGHLIN KEVIN F	Director	May 07 '25	Option Exercise	2.76	7,000	19,320	22,100	May 09 04:05 PM
MCLAUGHLIN KEVIN F	Director	May 07 '25	Sale	39.98	7,000	279,860	15,100	May 09 04:05 PM
MCLAUGHLIN KEVIN F	Director	May 07 '25	Proposed Sale	39.98	7,000	279,878		May 07 04:12 PM
Colangelo Dominick	President and CEO	Apr 09 '25	Option Exercise	2.75	24,850	68,338	285,204	Apr 11 04:05 PM
Colangelo Dominick	President and CEO	Apr 10 '25	Option Exercise	2.75	24,850	68,338	285,204	Apr 11 04:05 PM
Colangelo Dominick	President and CEO	Apr 10 '25	Sale	41.89	24,850	1,040,966	260,354	Apr 11 04:05 PM
Colangelo Dominick	President and CEO	Apr 09 '25	Sale	41.11	24,850	1,021,584	260,354	Apr 11 04:05 PM
Colangelo Dominick	Officer	Apr 10 '25	Proposed Sale	41.89	24,850	1,040,865		Apr 10 04:17 PM
Colangelo Dominick	Officer	Apr 09 '25	Proposed Sale	41.11	24,850	1,021,686		Apr 09 04:08 PM
Colangelo Dominick	President and CEO	Mar 13 '25	Option Exercise	1.95	26,592	51,854	286,589	Mar 14 04:07 PM
Colangelo Dominick	President and CEO	Mar 12 '25	Option Exercise	1.95	26,591	51,852	286,588	Mar 14 04:07 PM
Colangelo Dominick	President and CEO	Mar 12 '25	Sale	46.31	26,591	1,231,429	259,997	Mar 14 04:07 PM
Colangelo Dominick	President and CEO	Mar 13 '25	Sale	45.78	26,592	1,217,382	259,997	Mar 14 04:07 PM
Colangelo Dominick	Officer	Mar 13 '25	Proposed Sale	45.78	26,592	1,217,281		Mar 13 04:19 PM
Colangelo Dominick	Officer	Mar 12 '25	Proposed Sale	46.31	26,591	1,231,364		Mar 12 04:14 PM
Halpin Michael	Chief Operating Officer	Mar 03 '25	Option Exercise	16.66	10,000	166,600	25,359	Mar 05 04:05 PM
Halpin Michael	Chief Operating Officer	Mar 03 '25	Sale	49.52	10,000	495,200	15,539	Mar 05 04:05 PM
Hagen Heidi	Director	Mar 03 '25	Option Exercise	3.74	9,000	33,660	37,650	Mar 05 04:05 PM
Hagen Heidi	Director	Mar 03 '25	Sale	49.53	9,000	445,770	28,650	Mar 05 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Mar 03 '25	Sale	49.53	9,000	445,770	13,967	Mar 05 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Mar 03 '25	Option Exercise	18.00	10,000	180,000	76,101	Mar 05 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Mar 03 '25	Sale	49.53	10,000	495,300	66,101	Mar 05 04:05 PM
Hagen Heidi	Director	Mar 03 '25	Proposed Sale	51.20	9,000	460,800		Mar 03 11:29 AM
Hopper Jonathan Mark	Officer	Mar 03 '25	Proposed Sale	51.20	10,000	512,000		Mar 03 11:04 AM
Mara Joseph Anthony Jr	Officer	Mar 03 '25	Proposed Sale	51.20	9,000	460,800		Mar 03 11:00 AM
Halpin Michael	Officer	Mar 03 '25	Proposed Sale	51.20	10,000	512,000		Mar 03 10:47 AM
Hopper Jonathan Mark	Chief Medical Officer	Feb 24 '25	Option Exercise	0.00	1,500	0	66,737	Feb 26 04:05 PM
Colangelo Dominick	President and CEO	Feb 24 '25	Option Exercise	0.00	18,250	0	268,456	Feb 26 04:05 PM
Halpin Michael	Chief Operating Officer	Feb 24 '25	Option Exercise	0.00	5,250	0	18,025	Feb 26 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Feb 24 '25	Option Exercise	0.00	4,625	0	24,325	Feb 26 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 24 '25	Option Exercise	0.00	3,000	0	3,756	Feb 26 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 25 '25	Sale	52.07	1,669	86,905	756	Feb 26 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 24 '25	Option Exercise	0.00	1,875	0	3,081	Feb 26 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 25 '25	Sale	52.07	1,137	59,204	1,206	Feb 26 04:05 PM
Flynn Sean C.	Officer	Feb 25 '25	Proposed Sale	52.07	1,669	86,905		Feb 25 12:20 PM
SIEGAL JONATHAN	Officer	Feb 25 '25	Proposed Sale	52.07	1,137	59,204		Feb 25 12:00 PM
Flynn Sean C.	Chief Legal Officer	Feb 20 '25	Sale	57.32	3,835	219,822	756	Feb 24 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Feb 19 '25	Option Exercise	0.00	1,750	0	64,590	Feb 20 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Feb 18 '25	Option Exercise	0.00	2,325	0	63,825	Feb 20 04:05 PM
Colangelo Dominick	President and CEO	Feb 19 '25	Option Exercise	0.00	8,938	0	254,402	Feb 20 04:05 PM
Colangelo Dominick	President and CEO	Feb 18 '25	Option Exercise	0.00	11,700	0	250,887	Feb 20 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 19 '25	Option Exercise	0.00	1,750	0	5,368	Feb 20 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 18 '25	Option Exercise	0.00	5,325	0	4,650	Feb 20 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Feb 18 '25	Option Exercise	0.00	7,379	0	20,509	Feb 20 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 18 '25	Option Exercise	0.00	2,920	0	3,706	Feb 20 04:05 PM
Halpin Michael	Chief Operating Officer	Feb 19 '25	Option Exercise	0.00	2,813	0	14,107	Feb 20 04:05 PM
Halpin Michael	Chief Operating Officer	Feb 18 '25	Option Exercise	0.00	9,075	0	13,106	Feb 20 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 19 '25	Sale	56.72	1,710	96,991	1,206	Feb 20 04:05 PM
Flynn Sean C.	Officer	Feb 20 '25	Proposed Sale	57.32	3,835	219,822		Feb 20 11:14 AM
SIEGAL JONATHAN	Officer	Feb 19 '25	Proposed Sale	56.72	1,710	96,991		Feb 19 09:54 AM

AKBA

Akebia Therapeutics Inc

VCEL

Vericel Corp

Upgrade your FINVIZ experience